LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 41

Search options

  1. Article: Overexpression of mitogen-activated protein kinase phosphatase-1 in endothelial cells reduces blood-brain barrier injury in a mouse model of ischemic stroke.

    Qin, Xiu-De / Yang, Tai-Qin / Zeng, Jing-Hui / Cai, Hao-Bin / Qi, Shao-Hua / Jiang, Jian-Jun / Cheng, Ying / Xu, Long-Sheng / Bu, Fan

    Neural regeneration research

    2023  Volume 18, Issue 8, Page(s) 1743–1749

    Abstract: Ischemic stroke can cause blood-brain barrier (BBB) injury, which worsens brain damage induced by stroke. Abnormal expression of tight junction proteins in endothelial cells (ECs) can increase intracellular space and BBB leakage. Selective inhibition of ... ...

    Abstract Ischemic stroke can cause blood-brain barrier (BBB) injury, which worsens brain damage induced by stroke. Abnormal expression of tight junction proteins in endothelial cells (ECs) can increase intracellular space and BBB leakage. Selective inhibition of mitogen-activated protein kinase, the negative regulatory substrate of mitogen-activated protein kinase phosphatase (MKP)-1, improves tight junction protein function in ECs, and genetic deletion of MKP-1 aggravates ischemic brain injury. However, whether the latter affects BBB integrity, and the cell type-specific mechanism underlying this process, remain unclear. In this study, we established an adult male mouse model of ischemic stroke by occluding the middle cerebral artery for 60 minutes and overexpressed MKP-1 in ECs on the injured side via lentiviral transfection before stroke. We found that overexpression of MKP-1 in ECs reduced infarct volume, reduced the level of inflammatory factors interleukin-1β, interleukin-6, and chemokine C-C motif ligand-2, inhibited vascular injury, and promoted the recovery of sensorimotor and memory/cognitive function. Overexpression of MKP-1 in ECs also inhibited the activation of cerebral ischemia-induced extracellular signal-regulated kinase (ERK) 1/2 and the downregulation of occludin expression. Finally, to investigate the mechanism by which MKP-1 exerted these functions in ECs, we established an ischemic stroke model in vitro by depriving the primary endothelial cell of oxygen and glucose, and pharmacologically inhibited the activity of MKP-1 and ERK1/2. Our findings suggest that MKP-1 inhibition aggravates oxygen and glucose deprivation-induced cell death, cell monolayer leakage, and downregulation of occludin expression, and that inhibiting ERK1/2 can reverse these effects. In addition, co-inhibition of MKP-1 and ERK1/2 exhibited similar effects to inhibition of ERK1/2. These findings suggest that overexpression of MKP-1 in ECs can prevent ischemia-induced occludin downregulation and cell death via deactivating ERK1/2, thereby protecting the integrity of BBB, alleviating brain injury, and improving post-stroke prognosis.
    Language English
    Publishing date 2023-02-23
    Publishing country India
    Document type Journal Article
    ZDB-ID 2388460-5
    ISSN 1876-7958 ; 1673-5374
    ISSN (online) 1876-7958
    ISSN 1673-5374
    DOI 10.4103/1673-5374.363836
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Alpha-Synuclein Accumulation and Its Phosphorylation in the Enteric Nervous System of Patients Without Neurodegeneration: An Explorative Study.

    Bu, Lu-Lu / Huang, Kai-Xun / Zheng, De-Zhi / Lin, Dan-Yu / Chen, Ying / Jing, Xiu-Na / Liang, Yan-Ran / Tao, En-Xiang

    Frontiers in aging neuroscience

    2020  Volume 12, Page(s) 575481

    Abstract: Alpha-synuclein (α-Syn) is widely distributed and involved in the regulation of the nervous system. The phosphorylation of α-Syn at serine 129 ( ... ...

    Abstract Alpha-synuclein (α-Syn) is widely distributed and involved in the regulation of the nervous system. The phosphorylation of α-Syn at serine 129 (p
    Language English
    Publishing date 2020-11-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2558898-9
    ISSN 1663-4365
    ISSN 1663-4365
    DOI 10.3389/fnagi.2020.575481
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: T cells and blood vessels: costimulation turns up the pressure.

    Bu, De-Xiu / Lichtman, Andrew H

    Circulation

    2010  Volume 122, Issue 24, Page(s) 2495–2498

    MeSH term(s) Animals ; Blood Vessels/immunology ; Blood Vessels/pathology ; Blood Vessels/physiopathology ; Humans ; Hypertension/immunology ; Hypertension/pathology ; Hypertension/physiopathology ; Immunity, Cellular ; Inflammation/immunology ; Inflammation/pathology ; Inflammation/physiopathology ; Lymphocyte Activation/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/pathology
    Language English
    Publishing date 2010-11-29
    Publishing country United States
    Document type Comment ; Editorial ; Research Support, N.I.H., Extramural
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.110.991059
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: IKK{szligbeta}-dependent NF-[kappa]B pathway controls vascular inflammation and intimal hyperplasia

    Bu, De-xiu / Erl, Wolfgang / de Martin, Rainer / Hansson, Göran K / Yan, Zhong-qun

    FASEB journal : 2005 Aug., v. 19, no. 10

    2005  

    Language English
    Dates of publication 2005-08
    Size p. 1293-1295.
    Document type Article
    ZDB-ID 639186-2
    ISSN 1530-6860 ; 0892-6638
    ISSN (online) 1530-6860
    ISSN 0892-6638
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  5. Article ; Online: Nuclear factor {kappa}B-mediated transactivation of telomerase prevents intimal smooth muscle cell from replicative senescence during vascular repair.

    Bu, De-xiu / Johansson, Maria E / Ren, Jingyi / Xu, Da-wei / Johnson, F Brad / Edfeldt, Kristina / Yan, Zhong-qun

    Arteriosclerosis, thrombosis, and vascular biology

    2010  Volume 30, Issue 12, Page(s) 2604–2610

    Abstract: ... to the replicative longevity of vascular cells. We found that TERT was de novo activated in the intima of injured ... vascular injury.: Conclusions: These results support a model in which vascular injury induces de novo ...

    Abstract Objective: To gain insights into mechanisms by which intimal hyperplasia interferes with the repair process by investigating expression and function of the catalytic telomerase reverse transcriptase (TERT) subunit after vascular injury.
    Methods and results: Functional telomerase is essential to the replicative longevity of vascular cells. We found that TERT was de novo activated in the intima of injured arteries, involving activation of the nuclear factor κB pathway. Stimulation of the isolated intimal smooth muscle cell (SMC) by basic fibroblast growth factor or tumor necrosis factor α resulted in increased TERT activity. This depends on the activation of c-Myc signaling because mutation of the E-box in the promoter or overexpression of mitotic arrest deficient 1 (MAD1), a c-Myc competitor, abrogated the transcriptional activity. Inhibition of nuclear factor κB in both intimal SMCs and the injured artery attenuated TERT transcriptional activity through reduction of c-Myc expression. Pharmacological blockade of TERT led to SMC senescence. Finally, depletion of telomerase function in mice resulted in severe intimal SMC senescence after vascular injury.
    Conclusions: These results support a model in which vascular injury induces de novo expression of TERT in intimal SMCs via activation of nuclear factor κB and upregulation of c-Myc. The resumed TERT activity is critical for intimal hyperplasia.
    MeSH term(s) Aminobenzoates/pharmacology ; Animals ; Binding Sites ; Carotid Artery Injuries/enzymology ; Carotid Artery Injuries/genetics ; Carotid Artery Injuries/pathology ; Cell Proliferation/drug effects ; Cells, Cultured ; Cellular Senescence/drug effects ; Disease Models, Animal ; Enzyme Inhibitors/pharmacology ; Fibroblast Growth Factor 2/metabolism ; Gene Expression Regulation, Enzymologic ; Hyperplasia ; I-kappa B Kinase/genetics ; I-kappa B Kinase/metabolism ; Male ; Mice ; Mice, Knockout ; Myocytes, Smooth Muscle/drug effects ; Myocytes, Smooth Muscle/enzymology ; Myocytes, Smooth Muscle/pathology ; NF-kappa B/metabolism ; Naphthalenes/pharmacology ; Promoter Regions, Genetic ; Proto-Oncogene Proteins c-myc/metabolism ; RNA/genetics ; RNA, Messenger/metabolism ; Rats ; Rats, Sprague-Dawley ; Telomerase/antagonists & inhibitors ; Telomerase/deficiency ; Telomerase/genetics ; Telomerase/metabolism ; Transcriptional Activation ; Transduction, Genetic ; Tumor Necrosis Factor-alpha/metabolism ; Tunica Intima/drug effects ; Tunica Intima/enzymology ; Tunica Intima/pathology
    Chemical Substances Aminobenzoates ; BIBR 1532 ; Enzyme Inhibitors ; NF-kappa B ; Naphthalenes ; Proto-Oncogene Proteins c-myc ; RNA, Messenger ; Tumor Necrosis Factor-alpha ; telomerase RNA ; Fibroblast Growth Factor 2 (103107-01-3) ; RNA (63231-63-0) ; I-kappa B Kinase (EC 2.7.11.10) ; Telomerase (EC 2.7.7.49) ; Tert protein, mouse (EC 2.7.7.49)
    Language English
    Publishing date 2010-09-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/ATVBAHA.110.213074
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia.

    Bu, De-xiu / Erl, Wolfgang / de Martin, Rainer / Hansson, Göran K / Yan, Zhong-qun

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

    2005  Volume 19, Issue 10, Page(s) 1293–1295

    Abstract: Nuclear factor-kappaB (NF-kappaB)-mediated vascular inflammation is a prominent characteristic of atherogenesis and restenosis. We noted that angioplastic injury to carotid artery elicited two phases of NF-kappaB activation characterized by an early ... ...

    Abstract Nuclear factor-kappaB (NF-kappaB)-mediated vascular inflammation is a prominent characteristic of atherogenesis and restenosis. We noted that angioplastic injury to carotid artery elicited two phases of NF-kappaB activation characterized by an early activation in the arterial media and a late activation coupled with high levels of inhibitor of IkappaB kinase (IKK) activity in intima. These findings prompted us to elucidate the role for the different phases of NF-kappaB activation and IKK in the progress of vascular repair. Our results show that blockade of the early NF-kappaB activation by perivascular administration of pyrrolidine dithiocarbamate transiently attenuates the expression of proinflammatory genes in the injured vessels but does not affect intimal formation. Interruption of IKKbeta by overexpressing a dominant-negative IKKbeta in the injured artery effectively inhibited the late phase of NF-kappaB activation, resulting in down-regulation of inducible nitric oxide synthase, tumor necrosis factor alpha, and monocyte chemoattractant protein-1 expression in conjunction with a 36% reduction in intima size, albeit with a lack of inhibitory effect on the early NF-kappaB activation. Collectively, these findings show that the IKKbeta-mediated late-phase NF-kappaB activation contributes to intimal hyperplasia and the accompanied vascular inflammatory responses.
    MeSH term(s) Angioplasty/adverse effects ; Animals ; Apoptosis ; Carotid Arteries/pathology ; Cell Proliferation ; Hyperplasia ; I-kappa B Kinase/physiology ; Male ; Muscle, Smooth, Vascular/pathology ; NF-kappa B/physiology ; Rats ; Rats, Sprague-Dawley ; Signal Transduction/physiology ; Tunica Intima/pathology ; Vasculitis/etiology
    Chemical Substances NF-kappa B ; I-kappa B Kinase (EC 2.7.11.10)
    Language English
    Publishing date 2005-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639186-2
    ISSN 1530-6860 ; 0892-6638
    ISSN (online) 1530-6860
    ISSN 0892-6638
    DOI 10.1096/fj.04-2645fje
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Mechanisms for the anti-inflammatory effects of statins.

    Bu, De-xiu / Griffin, Gabriel / Lichtman, Andrew H

    Current opinion in lipidology

    2011  Volume 22, Issue 3, Page(s) 165–170

    Abstract: Purpose of review: Statins have diverse effects on the cellular mediators of inflammation and immunity that may be partially responsible for their efficacy in preventing cardiovascular disease, and which have encouraged their use in treating immune/ ... ...

    Abstract Purpose of review: Statins have diverse effects on the cellular mediators of inflammation and immunity that may be partially responsible for their efficacy in preventing cardiovascular disease, and which have encouraged their use in treating immune/inflammatory diseases. We discuss a selection of recently published studies that provide new insights into the mechanisms by which statins exert anti-inflammatory effects.
    Recent findings: Statins have a variety of direct effects on the gene expression and function of cells of both the innate and adaptive immune systems, including endothelial cells, macrophages, dendritic cells and T cells. Many of these effects are related to statin blockade of GTPase isoprenylation, as has been shown in older literature, although newly identified cell type-specific downstream pathways of GTPase have been described. Recently published analyses of data from clinical trials have also provided further evidence that statin therapy has anti-inflammatory effects and benefits independent of lowering cholesterol.
    Summary: Ongoing research continues to strengthen the case that statins can modulate immune responses by several mechanisms, independent of lowering blood cholesterol. A major challenge for investigators will be to determine how to take advantage of these new mechanistic insights to improve treatment of cardiovascular disease and primary immune/inflammatory disorders.
    MeSH term(s) Adaptive Immunity/drug effects ; Animals ; Anti-Inflammatory Agents/pharmacology ; Clinical Trials as Topic ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Immunity, Innate/drug effects ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism
    Chemical Substances Anti-Inflammatory Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2011-04-15
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1045394-5
    ISSN 1473-6535 ; 0957-9672
    ISSN (online) 1473-6535
    ISSN 0957-9672
    DOI 10.1097/MOL.0b013e3283453e41
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for α-synuclein fibrils by SPR evaluation system.

    Chen, Yan-Fei / Bian, Jiang / Zhang, Peng / Bu, Lu-Lu / Shen, Yan / Yu, Wen-Bo / Lu, Xiu-Hong / Lin, Xin / Ye, De-Yong / Wang, Jian / Chu, Yong

    Bioorganic & medicinal chemistry

    2020  Volume 28, Issue 7, Page(s) 115358

    Abstract: PET imaging of α-synuclein (α-syn) deposition in the brain will be an effective tool for earlier diagnosis of Parkinson's disease (PD) due to α-syn aggregation is the widely accepted biomarker for PD. However, the necessary PET radiotracer for imaging is ...

    Abstract PET imaging of α-synuclein (α-syn) deposition in the brain will be an effective tool for earlier diagnosis of Parkinson's disease (PD) due to α-syn aggregation is the widely accepted biomarker for PD. However, the necessary PET radiotracer for imaging is clinically unavailable until now. The lead compound discovery is the first key step for the study. Herein, we initially established an efficient biologically evaluation system well in highthroughput based on SPR technology, and identified a novel class of N, N-dibenzylcinnamamide (DBC) compounds as α-syn ligands through the assay. These compounds were proved to have high affinities against α-syn aggregates (K
    MeSH term(s) Brain ; Cinnamates/chemistry ; Cinnamates/pharmacology ; Drug Design ; Humans ; Ligands ; Molecular Structure ; Positron-Emission Tomography ; Radioligand Assay ; alpha-Synuclein/chemistry
    Chemical Substances Cinnamates ; Ligands ; alpha-Synuclein
    Language English
    Publishing date 2020-02-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1161284-8
    ISSN 1464-3391 ; 0968-0896
    ISSN (online) 1464-3391
    ISSN 0968-0896
    DOI 10.1016/j.bmc.2020.115358
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.

    Hamuro, Lora / Kijanka, Grzegorz / Kinderman, Francis / Kropshofer, Harald / Bu, De-Xiu / Zepeda, Monica / Jawa, Vibha

    Journal of pharmaceutical sciences

    2017  Volume 106, Issue 10, Page(s) 2946–2954

    Abstract: An increasing number of therapeutic proteins are being developed for delivery through the subcutaneous (SC) route of administration. Relative to intravenous (IV) administration, the SC route offers more convenience to patients, flexibility in dosing, and ...

    Abstract An increasing number of therapeutic proteins are being developed for delivery through the subcutaneous (SC) route of administration. Relative to intravenous (IV) administration, the SC route offers more convenience to patients, flexibility in dosing, and potential to reduce health care costs. There is a perception that SC administration can pose a higher immunogenicity risk than IV administration for a given protein. To evaluate whether there is a difference in therapeutic protein immunogenicity associated with administration routes, a more detailed understanding of the interactions with the immune system by each route is needed. Few approved therapeutic proteins have available clinical immunogenicity data sets in the public domain that represent both IV and SC administration routes. This has prevented a direct comparison of the 2 routes of administration across a large sample size. Of the 6 marketed products where SC and IV route-related incidences of anti-drug antibody (ADA) were available, 4 were associated with higher immunogenicity incidence with SC. In other cases, there was no apparent difference between the SC and IV routes. Overall, the ADA incidence was low (<15%) with no impact on safety or efficacy. The challenges associated with identifying specific risk factors unique to SC administration are discussed.
    MeSH term(s) Administration, Intravenous/methods ; Animals ; Antibodies/immunology ; Antibody Formation/immunology ; Humans ; Injections, Intravenous/methods ; Injections, Subcutaneous/methods ; Proteins/immunology ; Risk Factors
    Chemical Substances Antibodies ; Proteins
    Language English
    Publishing date 2017-05-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 3151-3
    ISSN 1520-6017 ; 0022-3549
    ISSN (online) 1520-6017
    ISSN 0022-3549
    DOI 10.1016/j.xphs.2017.05.030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.

    Huang, Tao / Zhang, Sheng / Dai, De-Fang / Wang, Bu-Sen / Zhuang, Lu / Huang, Hai-Tao / Wang, Zhong-Fang / Zhao, Jun-Shi / Li, Qiu-Ping / Wu, Shi-Po / Wang, Xue / Zhang, Wen-Dan / Zhao, Zheng-Hao / Li, Hao / Zhang, Yan-Ping / Yang, Xiu-Liang / Jiang, Xin-Yang / Gou, Jin-Bo / Hou, Li-Hua /
    Gao, Li-Dong / Feng, Zhi-Chun

    The Lancet. Respiratory medicine

    2023  Volume 11, Issue 8, Page(s) 698–708

    Abstract: Background: Heterologous booster immunisation with orally administered aerosolised Ad5-nCoV vaccine (AAd5) has been shown to be safe and highly immunogenic in adults. Here, we aimed to assess the safety and immunogenicity of heterologous booster ... ...

    Abstract Background: Heterologous booster immunisation with orally administered aerosolised Ad5-nCoV vaccine (AAd5) has been shown to be safe and highly immunogenic in adults. Here, we aimed to assess the safety and immunogenicity of heterologous booster immunisation with orally administered AAd5 in children and adolescents aged 6-17 years who had received two doses of inactivated vaccine (BBIBP-CorV or CoronaVac).
    Methods: We did a randomised, open-label, parallel-controlled, non-inferiority study to assess the safety and immunogenicity of heterologous booster immunisation with AAd5 (0·1 mL) or intramuscular Ad5-nCoV vaccine (IMAd5; 0·3 mL) and homologous booster immunisation with inactivated vaccine (BBIBP-CorV or CoronaVac; 0·5 mL) in children (aged 6-12 years) and adolescents (aged 13-17 years) who had received two doses of inactivated vaccine at least 3 months earlier in Hunan, China. Children and adolescents who were previously immunised with two-dose BBIBP-CorV or CoronaVac were recruited for eligibility screening at least 3 months after the second dose. A stratified block method was used for randomisation, and participants were stratified by age and randomly assigned (3:1:1) to receive AAd5, IMAd5, or inactivated vaccine. The study staff and participants were not masked to treatment allocation. Laboratory and statistical staff were masked during the study. In this interim analysis, adverse events within 14 days and geometric mean titre (GMT) of serum neutralising antibodies on day 28 after the booster vaccination, based on the per-protocol population, were used as the primary outcomes. The analysis of non-inferiority was based on comparison using a one-sided 97·5% CI with a non-inferiority margin of 0·67. This study was registered at ClinicalTrials.gov, NCT05330871, and is ongoing.
    Findings: Between April 17 and May 28, 2022, 436 participants were screened and 360 were enrolled: 220 received AAd5, 70 received IMAd5, and 70 received inactivated vaccine. Within 14 days after booster vaccination, vaccine-related adverse reactions were reported: 35 adverse events (in 13 [12%] of 110 children and 22 [20%] of 110 adolescents) in 220 individuals in the AAd5 group, 35 (in 18 [51%] of 35 children and 17 [49%] of 35 adolescents) in 70 individuals in the IMAd5 group, and 13 (in five [14%] of 35 children and eight [23%] of 35 adolescents) in 70 individuals in the inactivated vaccine group. Solicited adverse reactions were also reported: 34 (13 [12%] of 110 children and 21 [10%] of 110 adolescents) in 220 individuals in the AAd5 group, 34 (17 [49%] of 35 children and 17 [49%] of 35 adolescents) in 70 individuals in the IMAd5 group, and 12 (five [14%] of 35 children and seven [20%] of 35 adolescents) in 70 individuals in the inactivated vaccine group. The GMTs of neutralising antibodies against ancestral SARS-CoV-2 Wuhan-Hu-1 (Pango lineage B) in the AAd5 group were significantly higher than the GMTs in the inactivated vaccine group (adjusted GMT ratio 10·2 [95% CI 8·0-13·1]; p<0·0001).
    Interpretation: Our study shows that a heterologous booster with AAd5 is safe and highly immunogenic against ancestral SARS-CoV-2 Wuhan-Hu-1 in children and adolescents.
    Funding: National Key R&D Program of China.
    MeSH term(s) Adult ; Humans ; Child ; Adolescent ; COVID-19 ; SARS-CoV-2 ; Vaccines, Inactivated ; Antibodies, Neutralizing
    Chemical Substances BIBP COVID-19 vaccine ; Ad5-nCoV vaccine (5AHC3V2UQS) ; sinovac COVID-19 vaccine ; Vaccines, Inactivated ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-05-17
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2686754-0
    ISSN 2213-2619 ; 2213-2600
    ISSN (online) 2213-2619
    ISSN 2213-2600
    DOI 10.1016/S2213-2600(23)00129-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top